D-0451-2025 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0451-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Feb 28, 2025 and is designated Class II. Reason for recall: CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit The recall status is ongoing. Affected quantity: 18,696 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 4, 2025
Initiation Date
Feb 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
18,696 bottles

Product description

Carvedilol Tablets USP 25 mg, 500 -Count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-165-05.

Reason for recall

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Distribution pattern

U.S. Nationwide

Code information

Lot, expiry: Lots 19231107, 19231114, 19231152, Exp Feb-25; Lot 19234866, Exp Jan-26

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0451-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0451-2025. Report a data issue: hello@regdatalab.com.